Photo of George Laliotis from bmmagazine.co.uk
Jun 26, 2024, 03:57
George Laliotis: Peri-operative FOLFIRINOX improved outcomes in patients with pancreatic cancer
George Laliotis, Translational Medicine Lead of GU Oncologist at shared a post by JAMA Oncology on X, adding:
“Check our latest work.
Peri-operative FOLFIRINOX improved outcomes in patients with pancreatic cancer. ctDNA detection after surgery by Signatera was highly predictive of post-surgery outcomes. Promising data that support the integration of ctDNA in pancreatic cancer care management.”
Quoting the post by JAMA Oncology:
“Peri-operative modified FOLFIRINOX was safe and effective, with a clinically meaningful improvement in survival compared with historical controls.”
Visit the article website.
Source: George Laliotis/X and JAMA Oncology/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18
Dec 21, 2024, 11:12
Dec 21, 2024, 11:06
Dec 21, 2024, 10:38